Phase 3Completed
Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)
A Phase 3b Randomised, Multicentre, Open-label Study Evaluating the Effectiveness of Switching to Two-monthly Long-acting Injectable Cabotegravir and Rilpivirine From First-line Oral Antiretroviral Therapy in HIV-1 Positive Virologically Suppressed Adults With a History of, or at Risk of, Sub-optimal HIV Control in Sub-Saharan Africa
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit (Academic or other)
- Enrolment
- 540 enrolled
- Conditions
- HIV-1-infection
- Interventions
- Cabotegravir/Rilpivirine; Antiretroviral
- Ages
- adults, older adults
- Registry
- NCT05546242
Full record on ClinicalTrials.gov
From the registry
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care. The study will seek to demonstrate non-inferior antiviral effectiveness of the 2-monthly long-acting injectable combination of cabotegravir/rilpivirine as compared to continuation of first line oral antiretroviral therapy.
Primary outcomes
- HIV-1 viral load at 12 months
History
Last registry update
Study completion
Primary completion
Started
Registered
Papers citing this trial
- Long-Acting HIV Therapy in African Adults with Adherence Challenges
The New England journal of medicine